Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT)
jumped 94.9% in the afternoon session after the company announced that its Phase 3 trial (ROSELLA) met its goal of improving progression-free survival and overall survival in treating resistant ovarian cancer with a new therapy (a combination of Relacorilant and Nab-paclitaxel).
Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in platinum-resistant ovarian cancer.
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
Corcept currently trades at $58.76 and has been a dream stock for shareholders. It’s returned 434% since March 2020, blowing past the S&P 500’s 117% gain. The company has also beaten the index over the past six months as its stock price is up 35.8%.
Uncover the potential of CORCEPT THERAPEUTICS INC, a growth stock reasonably priced. NASDAQ:CORT is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive valuation.
Growth boosts valuation multiples, but it doesn’t always last forever.
Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street.
Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQ:CORT) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best and worst performers in the branded pharmaceuticals industry.
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT)
fell 9.3% in the pre-market session after the company reported weak fourth quarter results: its revenue missed significantly, and its EPS fell short of Wall Street's estimates. Despite this, revenue grew 34% year-on-year, driven by increased adoption of Korlym, but higher operating expenses weighed on profitability.
On the other hand, Corcept provided optimistic full-year revenue guidance, which blew past analysts' expectations. Still, this quarter could have been better.
Biopharma company Corcept Therapeutics (NASDAQ:CORT) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 34.3% year on year to $181.9 million. On the other hand, the company’s full-year revenue guidance of $925 million at the midpoint came in 8.2% above analysts’ estimates. Its GAAP profit of $0.26 per share was 39% below analysts’ consensus estimates.
CORCEPT THERAPEUTICS INC was identified as an affordable growth stock. NASDAQ:CORT is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.
CORCEPT THERAPEUTICS INC could be undervalued. NASDAQ:CORT is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced.
